SOLVAY PHARMACEUTICALS COMPLETES ACQUISITION OF NEOPHARMA IN SWEDEN

Solvay Pharmaceuticals has announced the successful completion of the acquisition of Neopharma AB, a company based in Uppsala, Sweden, as shareholders representing 100 percent of the company's capital accepted the friendly takeover bid launched by Solvay last December. This acquisition, which values Neopharma AB at SEK 640 million (EUR 71 million), allows Solvay Pharmaceuticals to add the product Duodopa, an important new therapy for people suffering from advanced Parkinson's disease, to its product portfolio.

CompanynewsGroup (http://www.companynewsgroup.com/communique.asp?co_id=97083&r=Solvay)